SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.

Ratings Shijiazhuang Yiling Pharmaceutical Co., Ltd.

Equities

002603

CNE1000015S0

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 2025-07-15			5-day change	1st Jan Change
14.79 ^CNY	-1.14%		+0.48%	-7.62%

07-11	Yiling Pharmaceutical Receives Regulatory Greenlight for Review of Banxia Baizhu Tianma Granules	MT
07-08	Yiling Pharmaceutical Gets Nod to Trial G201-Na Capsule	MT

Summary: Shijiazhuang Yiling Pharmaceutical Co., Ltd.

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
From a short-term investment perspective, the company presents a deteriorated fundamental situation

Highlights: Shijiazhuang Yiling Pharmaceutical Co., Ltd.

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
The company is in a robust financial situation considering its net cash and margin position.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The opinion of analysts covering the stock has improved over the past four months.

Weaknesses: Shijiazhuang Yiling Pharmaceutical Co., Ltd.

The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Over the past four months, analysts' average price target has been revised downwards significantly.
Over the past twelve months, analysts' opinions have been revised negatively.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings Chart: Shijiazhuang Yiling Pharmaceutical Co., Ltd.

Source: Surperformance

ESG chart: Shijiazhuang Yiling Pharmaceutical Co., Ltd.

Source: MSCI

Sector Comparison:

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Global Valuation (Composite)	Capi.($)
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.		3.44B
DONG-E-E-JIAO CO.,LTD.		4.39B
TASLY PHARMACEUTICAL GROUP CO., LTD		3.24B
ZHEJIANG JOLLY PHARMACEUTICAL CO.,LTD	-	1.79B
HENAN LINGRUI PHARMACEUTICAL CO., LTD.		1.78B
TIANJIN CHASE SUN PHARMACEUTICAL CO.,LTD	-	1.64B
Average		2.71B
Weighted average by Cap.

See all sector ratings

Investor (Composite)

Trader (Composite)

ESG MSCI

Financials

Revenue growth

EPS growth

Capital Efficiency (Composite)

Net Margin

Financial Health (Composite)

Valuation

P/E

EV/Revenue

EV/EBITDA

PBR

Dividend Yield

Revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

Revenue revisions (1 month)

EPS revisions (1 year)

EPS revisions (4 months)

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (4 months)

Analysts' target price evolution (1 year)

Business Predictability

Surprise rates

Analysts' coverage

Analysts' recommendations divergence

Analysts' Target price divergence

Financial estimates divergence

ESG

Environment

Social

Governance

Controversy

Ethical controversies

Human rights controversies

Tax subsidies controversies

Sharia compliant

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes